Oncolytics Biotech (ONCY) Interest Expenses (2019 - 2025)

Oncolytics Biotech (ONCY) has 7 years of Interest Expenses data on file, last reported at $40.1 million in Q4 2025.

• On a quarterly basis, Interest Expenses rose 139779.33% year-over-year to $40.1 million in Q4 2025; TTM through Dec 2025 was $40.1 million, a 39453.9% increase from a year earlier, with the FY2025 full-year figure at $40.1 million, up 10.81% from the prior year.
• Interest Expenses for Q4 2025 stood at $40.1 million, up from $23979.0 in the prior quarter.
• Over the last five years, Interest Expenses for ONCY reached as high as $40.1 million in Q4 2025 and fell as low as -$103138.4 in Q4 2022.
• Historically, Interest Expenses has averaged $2.0 million across 5 years, with a median of $21332.1 in 2021.
• Across the five-year window, Interest Expenses plunged 597.12% in 2022 and surged 139779.33% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $20747.3 in 2021, then plunged by 597.12% to -$103138.4 in 2022, then jumped by 112.82% to $13221.6 in 2023, then surged by 116.57% to $28634.0 in 2024, then jumped by 139779.33% to $40.1 million in 2025.
• Per Business Quant data, the three most recent Interest Expenses figures were $40.1 million in Q4 2025, $23979.0 in Q3 2025, and $25259.9 in Q2 2025.